
|Videos|June 21, 2019
Dr Stephen Silberstein on How Patients Are Reacting to CGRP Inhibitors
Stephen Silberstein, MD, director of the Jefferson Headache Center, discusses patient reactions to being prescribed a CGRP inhibitor.
Advertisement
Stephen Silberstein, MD, director of the Jefferson Headache Center, discusses patient reactions to being prescribed a CGRP inhibitor.
Transcript:
How have patients reacted to being prescribed [calcitonin gene-related peptide] CGRP inhibitors?
In contrast to what we believed, patients are calling and rushing into the office to get the CGRP drugs because they're safe, they're effective, [they have] minimal if any side effects, and they don't have to take a pill every day.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Advances in MASLD and MASH Care Highlight Progress and Persistent Gaps
2
Howard A. “Skip” Burris, III, MD: An Oncology Pioneer Reflects on Patients, Progress, and Purpose
3
Employer Premiums and Deductibles Consume Significant Portion of Income in 19 States
4
Patients With Long-Term Conditions Prefer Remote Visits for Routine Care
5
















